However, the company opted to buy Nimbus Therapeutics' acetyl-CoA carboxylase (ACC) programme instead. Gilead will buy Nimbus Therapeutics' liver drug subsidiary Nimbus Apollo in a $1.2 billion deal.

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug ...

This week saw a series of big-ticket funding rounds for biotech companies, with Apollo Therapeutics and Nimbus Therapeutics both pulling in upwards of $200 million, in a positive sign for private ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after 12 years in management at Japan's biggest ...

Nimbus Therapeutics has used these approaches and established a successful track record of delivering clinical candidates for targets such as Tyk2 and HPK1 that have proven difficult for other drug ...